Eli Lilly and Company $LLY Shares Purchased by WealthBridge Capital Management LLC

WealthBridge Capital Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,858 shares of the company’s stock after acquiring an additional 155 shares during the quarter. Eli Lilly and Company makes up about 1.2% of WealthBridge Capital Management LLC’s investment portfolio, making the stock its 19th largest position. WealthBridge Capital Management LLC’s holdings in Eli Lilly and Company were worth $4,567,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth $27,000. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company during the second quarter worth about $31,000. Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 2nd quarter valued at about $35,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on LLY shares. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Finally, Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,027.95.

Eli Lilly and Company Trading Up 1.4%

Shares of NYSE LLY opened at $1,058.05 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $1.00 trillion, a PE ratio of 69.15, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,066.65. The stock has a fifty day simple moving average of $855.89 and a 200-day simple moving average of $787.66.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.